Factor Viii Inhibitors-Reference-Cited by-同舟云学术

Factor Viii Inhibitors

Published:2001 Issue: Volume: Page:65-73
ISSN:0065-2598
Container-title:Advances in Experimental Medicine and Biology
language:
Short-container-title:

Author:

Lollar Pete,Healey John F.,Barrow Rachel T.,Parker Ernest T.

Publisher

Springer US

Link

http://link.springer.com/content/pdf/10.1007/978-1-4615-1277-6_6

Reference45 articles.

1. Hoyer, L.W. and D. Scandella. 1994. Factor VIII inhibitors: structure and function in autoantibody and hemophilia A patients. Semin.Hematol. 31:1–5.

2. Scandella, D., C. Kessler, P. Esmon, D. Hurst, S. Courter, E. Gomperts, M. Fetch, and R. Prescott. 1995. Epitope specificity and functional characterization of factor VIII inhibitors. Advances in Experimental Medicine & Biology 386:47–63.

3. Scandella, D. 1996. Human anti-factor VIII antibodies: epitope localization and inhibitory function. Vox Sanguinis 70 Suppl 1:9–14.

4. Lollar, P. 1997. Analysis of factor VIII inhibitors using hybrid human/porcine factor VIII. Thromb.Haemostas. 78:647–651.

5. Lusher, J.M., S. Arkin, C.F. Abildgaard, R.S. Schwartz, and Kogenate Previously Untreated Patient Study Group. 1993. Recombinant factor VIII for the treatment of previously untreated patients with hemophilia A. Safety, efficacy, and the development of inhibitors. N.Engl.J.Med. 328:453–459.

Cited by 26 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Immunogenicity of Therapeutic Biological Modalities - Lessons from Hemophilia A Therapies;Journal of Pharmaceutical Sciences;2023-09

2. Phosphatidylserine-mediated oral tolerance;Cellular Immunology;2023-02

3. Biophysical Characterization of Tolerogenic Lipid-Based Nanoparticles Containing Phosphatidylcholine and Lysophosphatidylserine;Journal of Pharmaceutical Sciences;2022-07

4. Rational design of a nanoparticle platform for oral prophylactic immunotherapy to prevent immunogenicity of therapeutic proteins;Scientific Reports;2021-09-08

5. Biological Function and Immunotherapy Utilizing Phosphatidylserine-based Nanoparticles;Immunological Investigations;2020-03-23